Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of Irofulven as First Line Therapy in Recurrent or Metastatic Gastric Cancer

NCT00062257 is registered in ClinicalTrials.gov with Cancer Therapeutics Research Group as lead sponsor.

NCT NCT00062257
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00062257 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of Irofulven as First Line Therapy in Recurrent or Metastatic Gastric Cancer
Lead sponsor
Cancer Therapeutics Research Group
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2003
Completion date
September 30, 2006
Enrollment
Not reported
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer